Genmab Announces Results of Ofatumumab Phase II Study in Multiple Sclerosis
GSK and Genmab Announce Start of Ofatumumab Phase III Combination Study in Non-Hodgkin’s Lymphoma
14-Sep-2010 -
Genmab A/S announced encouraging results from an ofatumumab Phase II safety and pharmacokinetics study in patients with relapsing-remitting multiple sclerosis (RRMS).
A total of 38 patients were included in this double-blind, dose escalation trial. Patients were randomized to receive two ...
human antibodies
lymphoma
magnetic resonance imaging
+2